February 9, 2024 — An innovative breast imaging technique provides high sensitivity for detecting cancer while significantly reducing the likelihood of false positive results, according to a study published today in Radiology: Imaging Cancer, a journal of the Radiological Society of North America (RSNA). Researchers said the technique has the potential to offer more reliable breast cancer screening for a broader range of patients.
Mammography is an effective screening tool for early detection of breast cancer, but its sensitivity is reduced in dense breast tissue. This is due to the masking effect of overlying dense fibroglandular tissue. Since almost half of the screening population has dense breasts, many of these patients require additional breast imaging, often with MRI, after mammography.
Low-dose positron emission mammography (PEM) is a novel molecular imaging technique that provides improved diagnostic performance at a radiation dose comparable to that of mammography.
For the study, 25 women, median age 52, recently diagnosed with breast cancer, underwent low-dose PEM with the radiotracer fluorine 18-labeled fluorodeoxyglucose (18F-FDG). Two breast radiologists reviewed PEM images taken one and four hours post 18F-FDG injection and correlated the findings with lab results.
PEM displayed comparable performance to MRI, identifying 24 of the 25 invasive cancers (96%). Its false positive rate was only 16%, compared with 62% for MRI.
Along with its strong sensitivity and low false-positive rate, PEM could potentially decrease downstream healthcare costs as this study shows it may prevent further unnecessary work up compared to MRI. Additionally, the technology is designed to deliver a radiation dose comparable to that of traditional mammography without the need for breast compression, which can often be uncomfortable for patients.
“The integration of these features—high sensitivity, lower false-positive rates, cost-efficiency, acceptable radiation levels without compression, and independence from breast density—positions this emerging imaging modality as a potential groundbreaking advancement in the early detection of breast cancer,” said study lead author Vivianne Freitas, M.D., M.Sc., assistant professor at the University of Toronto. “As such, it holds the promise of transforming breast cancer diagnostics and screening in the near future, complementing or even improving current imaging methods, marking a significant step forward in breast cancer care.”
Low-dose PEM offers potential clinical uses in both screening and diagnostic settings, according to Dr. Freitas.
“For screening, its ability to perform effectively regardless of breast density potentially addresses a significant shortcoming of mammography, particularly in detecting cancers in dense breasts where lesions may be obscured,” she said. “It also presents a viable option for patients at high risk who are claustrophobic or have contraindications for MRI.”
The technology could also play a crucial role in interpreting uncertain mammogram results, evaluating the response to chemotherapy and ascertaining the extent of disease in newly diagnosed breast cancer, including involvement of the other breast.
Dr. Freitas, who is also staff radiologist of the Breast Imaging Division of the Toronto Joint Department of Medical Imaging, University Health Network, Sinai Health System and Women’s College Hospital, is currently researching PEM’s ability to reduce the high rates of false positives typically associated with MRI scans. Should PEM successfully lower these rates, it could significantly lessen the emotional distress and anxiety linked to false positives, Dr. Freitas said. Additionally, it might lead to a decrease in unnecessary biopsies and treatments.
More studies are needed to determine low-dose PEM’s exact role and efficacy in the clinical setting.
“While the full integration of this imaging method into clinical practice is yet to be confirmed, the preliminary findings of this research are promising, particularly in demonstrating the capability of detecting invasive breast cancer with low doses of fluorine-18-labeled FDG,” Dr. Freitas said. “This marks a critical first step in its potential future implementation in clinical practice.”
For more information: www.rsna.org